Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular Carcinoma
Principal Investigator
Laura Dawson, MD
Status
Terminated
Date Opened To Accrual
April 24 2013
Date Closed to Accrual
March 10 2021
Date of Study Termination
September 04 2025
Disease Site
Gastrointestinal [GI]
Liver
Phase
III
Developmental Therapeutics
No
Primary Objective
To determine if SBRT improves overall survival in HCC patients treated with Sorafenib
Patient Population
Unsuitable for resection or transplant or radiofrequency ablation (RFA); Unsuitable for TACE or refractory to TACE; Barcelona Clinic Liver Cancer Stage (BCLC) Intermediate (B) or Advanced (C)
Target Accrual
292
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.